HSP70 Inhibition Blocks Adaptive Resistance and Synergizes with MEK Inhibition for the Treatment of NRAS-mutant Melanoma
Overview
Authors
Affiliations
Significance: MEK inhibitors are currently used for NRAS-mutant melanoma, but have shown modest efficacy as single agents. This research shows a synergistic effect of combining HSP70 inhibitors with MEK inhibitors for the treatment of NRAS mutant melanoma.
An African-Specific Variant of TP53 Reveals PADI4 as a Regulator of p53-Mediated Tumor Suppression.
Indeglia A, Leung J, Miller S, Leu J, Dougherty J, Clarke N Cancer Discov. 2023; 13(7):1696-1719.
PMID: 37140445 PMC: 10326602. DOI: 10.1158/2159-8290.CD-22-1315.
Leu J, Murphy M, George D ACS Chem Biol. 2022; 17(5):1038-1044.
PMID: 35420772 PMC: 9208338. DOI: 10.1021/acschembio.2c00113.